The researchers analyzed the IgG glycome composition in 5,080 samples from 1,940 women in the transition from premenopause (perimenopause) to postmenopause. Many of these samples were obtained from TwinsUK, the largest registry of twins in the UK and led by researchers from King’s College London.
Analysis of IgG glycome in multiple samples from the same individual may reveal an association between perimenopause and changes in IgG glycome composition. This stage shows that the IgG glycome changes from an inhibitor of inflammation to a pro-inflammatory. While this is common as we age, researchers have seen this change happen rapidly as women transition from a normal cycle to menopause.
This shift in IgG glycans is associated with many of the health risks that come with menopause. In some diseases such as rheumatoid arthritis and cardiovascular diseases, this change can occur years before the onset of the disease. This suggests that glycan and chronic inflammation are involved and that the variation of IgG glycans plays a role in disease development.
Due to poor awareness and inappropriate use of hormone tests, women are often misdiagnosed with conditions such as fibromyalgia, migraines, depression, or chronic fatigue syndrome and are frequently prescribe antidepressants despite a lack of evidence to support their use to improve low mood associated with perimenopause or menopause. This study shows that IgG glycan can be used to predict perimenopause.
Dr Cristina Menni, from TwinsUK and King’s College London, said: “Perimenopause is poorly diagnosed due to highly irregular hormonal cycles and symptoms that can persist for up to 15 years. Currently, no have an accurate diagnostic test for perimenopause Adding easily quantifiable Early Biomarkers of perimenopause could be a valuable improvement to current clinical treatments now. “